PT-141 (Bremelanotide)
Also Known AsBremelanotide · BMT-141 · Vyleesi
Developed by Palatin Technologies from Melanotan II, itself a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). PT-141 was isolated as the active cyclic heptapeptide metabolite responsible for the melanocortin-mediated sexual arousal effects observed during Melanotan II research. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
How PT-141 Works
Melanocortin-4 Receptor (MC4R) Agonism
PT-141 is a non-selective melanocortin receptor agonist with primary activity at MC4R. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 acts centrally in the hypothalamus to initiate sexual arousal through neural pathways, representing a fundamentally different pharmacological approach.
Central Nervous System Activation
Activates the medial preoptic area (MPOA) and paraventricular nucleus (PVN) of the hypothalamus, triggering descending pathways that modulate both psychological arousal and physiological sexual response. fMRI studies confirm increased brain activity in arousal-processing regions.
Oxytocin Release
MC4R activation in the PVN stimulates oxytocin release, which contributes to both the pro-sexual effects and the social bonding/intimacy aspects of the arousal response. This oxytocinergic component distinguishes melanocortin-based therapies from purely vascular approaches.
Published Research
Female Sexual Dysfunction (HSDD)
StrongTwo pivotal Phase 3 trials (RECONNECT, n=1,247) demonstrated statistically significant increases in desire and reductions in distress in premenopausal women with HSDD. The FDA approved bremelanotide (Vyleesi) in June 2019 based on these results, making it the first melanocortin-based therapy approved for sexual dysfunction.
Male Erectile Dysfunction
ModeratePhase 2 clinical trials demonstrated efficacy in men with erectile dysfunction, including those non-responsive to PDE5 inhibitors (sildenafil). The central mechanism of action provides a complementary approach for patients with psychogenic or mixed-etiology ED. Development for male indications was deprioritized commercially.
Melanocortin Neuroscience
StrongPT-141 serves as an important research tool for understanding the melanocortin system's role in sexual behavior, energy homeostasis, and stress response. It has advanced understanding of MC4R function, hypothalamic arousal circuits, and central vs. peripheral mechanisms of sexual response.
Safety Profile
FDA-approved safety profile from clinical trials involving >1,200 patients. Most common adverse effects: nausea (40%), flushing (20%), headache (11%), injection site reactions. Transient hypertension (systolic increase ~6 mmHg) observed. Contraindicated in uncontrolled hypertension and cardiovascular disease. Limited to 8 doses per month per prescribing guidelines due to nausea profile.
Handling & Storage
Reconstitute with bacteriostatic water. PT-141 is a cyclic heptapeptide with good aqueous stability. Store reconstituted solution at 2-8°C. Lyophilized powder stable at -20°C. Protect from light.
Peer-Reviewed Literature
- 1
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
Clayton AH, Althof SE, Kingsberg S, et al.
- 2
Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials (RECONNECT)
Kingsberg SA, Clayton AH, Portman D, et al.
- 3
Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist
Pfaus JG, Shadiack A, Van Soest T, et al.
- 4
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Diamond LE, Earle DC, Heiman JR, et al.
PT-141 FAQ
What is PT-141?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist. It acts centrally in the brain's hypothalamus to initiate sexual arousal, unlike PDE5 inhibitors which act on peripheral blood vessels. It was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
How is PT-141 different from Viagra/sildenafil?
PT-141 works through a fundamentally different mechanism. Sildenafil (Viagra) acts peripherally by inhibiting PDE5 to increase blood flow. PT-141 acts centrally in the brain by activating melanocortin-4 receptors (MC4R) in the hypothalamus, initiating both psychological arousal and physiological response through neural pathways.
Is PT-141 FDA-approved?
Yes. Bremelanotide (marketed as Vyleesi) was FDA-approved in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Approval was based on two Phase 3 RECONNECT trials enrolling over 1,200 patients. Research-grade PT-141 is sold for investigational use only.
What is the relationship between PT-141 and Melanotan II?
PT-141 is the cyclic heptapeptide active metabolite of Melanotan II. When Melanotan II was originally studied for tanning (melanogenesis), researchers observed unexpected pro-sexual effects. PT-141 was isolated as the specific fragment responsible for melanocortin-mediated sexual arousal, then developed as a standalone therapeutic compound.
PT-141 Products
All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.
PT-141
10mgThe sex drive peptide — works directly in your brain to ignite genuine sexual desire and arousal in both men and women. FDA-approved mechanism. This is the one everyone's talking about.
- Directly increases sexual desire and arousal in both men AND women
- Works through the brain — not blood flow — for genuine desire, not just mechanics
Explore Related Research
Kisspeptin
5mgThe master switch of your sex hormones — triggers the full cascade from brain to testosterone/estrogen production, boosting libido, arousal, and fertility in both sexes.
- Triggers the hormonal cascade that drives sex drive and arousal
- Boosts testosterone in men and estrogen in women naturally
Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.